Assignee
GI INNOVATION INC
KR·10 granted patents·14 pending applications·15 citations·filing 2019–2025
Top patents by PatentIndex Score
24 records- 0192US11857601B2Pharmaceutical composition for cancer treatment comprising fusion protein including IL-2 protein and CD80 protein and anticancer drugGI INNOVATION INC·Filed 2021·Granted Jan 2, 2024·3 cites·11 claims
- 0292US11492384B2Fusion protein comprising IL-2 protein and CD80 protein, and use thereofGI INNOVATION INC·Filed 2019·Granted Nov 8, 2022·6 cites·21 claims
- 0391US11639383B2Pharmaceutical composition for treatment of cancer, comprising an immune checkpoint inhibitor antibody and a fusion protein comprising an IL-2 mutant and a CD80 extracellular domainGI INNOVATION INC·Filed 2020·Granted May 2, 2023·3 cites·5 claims
- 0486US12478675B2Pharmaceutical composition for enhancing radiotherapy comprising fusion protein containing IL-2 protein and CD80 proteinGI INNOVATION INC·Filed 2021·Granted Nov 25, 2025·1 cites·26 claims
- 0580US12291555B2Fusion protein comprising IL-2 protein and CD80 protein, and use thereofGI INNOVATION INC·Filed 2022·Granted May 6, 2025·0 cites·20 claims
- 0680US12286464B2Fusion protein comprising IL-2 protein and CD80 protein, and use thereofGI INNOVATION INC·Filed 2022·Granted Apr 29, 2025·0 cites·20 claims
- 0777US12128076B2Composition comprising probiotics and polypeptide having binding affinity for IgE and use thereofGI INNOVATION INC·Filed 2019·Granted Oct 29, 2024·2 cites·6 claims
- 0876US2025230212A1Fusion protein comprising il-2 protein and cd80 protein, and use thereofGI INNOVATION INC·Filed 2025·Application pending·0 cites
- 0971US12414984B2Fusion protein comprising anti-CD73 antibody and IL-2, and use thereofGI INNOVATION INC·Filed 2024·Granted Sep 16, 2025·0 cites·12 claims
- 1070US2026062457A1Extracellular domain of alpha subunit of ige fc receptor, pharmaceutical composition comprising same and method for producing sameGI INNOVATION INC·Filed 2025·Application pending·0 cites
- 1168US2023257459A1Pharmaceutical composition for treatment of cancer, comprising an immune checkpoint inhibitor antibody and a fusion protein comprising an il-2 mutant and a cd80 extracellular domainGI INNOVATION INC·Filed 2023·Application pending·0 cites
- 1267US2026061032A1Fusion protein comprising anti-cd73 antibody and il-2, and use thereofGI INNOVATION INC·Filed 2025·Application pending·0 cites
- 1365US12410233B2Extracellular domain of alpha subunit of IgE Fc receptor, pharmaceutical composition comprising same and method for producing sameGI INNOVATION INC·Filed 2019·Granted Sep 9, 2025·0 cites·12 claims
- 1465US2026061022A1Polypeptide dimer with high sialic acid content, comprising extracellular domain of alpha subunit of ige fc receptor, and pharmaceutical composition comprising sameGI INNOVATION INC·Filed 2025·Application pending·0 cites
- 1564US2024058420A1Pharmaceutical composition for cancer treatment comprising fusion protein including il-2 protein and cd80 protein and anticancer drugGI INNOVATION INC·Filed 2023·Application pending·0 cites
- 1663US2023104217A1Fusion protein comprising il-2 protein and cd80 protein, and use thereofGI INNOVATION INC·Filed 2022·Application pending·0 cites
- 1761US2025099548A1Pharmaceutical composition for preventing or treating degenerative brain diseases, containing glucagon-like peptide-1 and interleukin-1 receptor antagonistGI INNOVATION INC·Filed 2023·Application pending·0 cites
- 1857US12409203B2Polypeptide dimer with high sialic acid content, comprising extracellular domain of alpha subunit of IGE FC receptor, and pharmaceutical composition comprising sameGI INNOVATION INC·Filed 2020·Granted Sep 9, 2025·0 cites·13 claims
- 1956US2024148829A1Formulation of fusion protein including extracellular domain of alpha subunit of ige fc receptorGI INNOVATION INC·Filed 2022·Application pending·0 cites
- 2054US2023357346A1Fusion protein including glucagon-like peptide-1 and interleukin-1 receptor antagonist and use thereofGI INNOVATION INC·Filed 2021·Application pending·0 cites
- 2153US2023257438A1Fusion protein comprising anti-lag-3 antibody and il-2, and use thereofGI INNOVATION INC·Filed 2021·Application pending·0 cites
- 2252US2023139890A1Fusion protein comprising il-2 protein and cd80 protein fragment or variant thereof, and uses thereofGI INNOVATION INC·Filed 2021·Application pending·0 cites
- 2352US2023125871A1Fusion protein preparation comprising il-2 and cd80 proteinsGI INNOVATION INC·Filed 2021·Application pending·0 cites
- 2450US2023279124A1Fusion protein comprising ige fc receptor alpha subunit extracellular domain and anti-il-4r antibody, and use thereofGI INNOVATION INC·Filed 2021·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when GI INNOVATION INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →